Latest news
ABCL635 Reduced Vasomotor Symptom Frequency and Severity in Phase 2 Trial - Patient Care OnlinePatient Care Online · Mon, 10 Aug 2026 15:11:15 GMTPhase 2 data: ABCL635 reduces frequency, severity of VMS symptoms - Contemporary OB/GYNContemporary OB/GYN · Mon, 10 Aug 2026 14:54:42 GMTAbCellera Announces Positive Phase 2 Top-Line Data for ABCL635 in Clinical Trial - Kalkine MediaKalkine Media · Mon, 10 Aug 2026 14:07:03 GMTAbCellera Stock Soars 30% After Menopause Drug ABCL635 Hits Phase 2 Success In Hot Flash Trial Results - International Business Times AustraliaInternational Business Times Australia · Mon, 10 Aug 2026 13:44:13 GMTAbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial - Yahoo FinanceYahoo Finance · Mon, 10 Aug 2026 13:03:44 GMTAbCellera shares surge 22% after ABCL635 delivers positive Phase 2 results - Yahoo FinanceYahoo Finance · Mon, 10 Aug 2026 12:45:25 GMTAbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - Business WireBusiness Wire · Mon, 10 Aug 2026 11:00:00 GMTEraNova Announces Positive Preliminary Economic Assessment for the Adanac Molybdenum Project: After-Tax NPV of $714.4 Million and 23.5% IRR - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 11:54:00 GMT